Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys

J Toxicol Sci. 2007 Oct;32(4):411-20. doi: 10.2131/jts.32.411.

Abstract

Toxicity screening of a newly developed oral heparin derivative was carried out in twelve male cynomolgus monkeys (Macaca fascicularis), composed of three treatment and vehicle control groups. A newly orally active heparin derivative, developed by Seoul National University, was given to the treatment group at three doses with low (12.8 mg/kg), medium (89.6 mg/kg) and high (640 mg/kg) doses for 14 days. A treatment group did not show any change in body weights, hematological parameters (e.g., RBC, WBC, platelet, PDW, MPV, etc.) and serum biochemical parameters (e.g., AST, ALT, BUN, etc.) for 2 weeks compared with those of the vehicle control group. These findings indicated that the oral anticoagulant drug, a newly developed oral heparin derivative, did not have any toxic effect for 2 week in this study. The present study will be valuable in the proper interpretation for non-clinical study using cynomolgus monkeys in the development of a new drug of heparin derivative.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Anticoagulants / chemistry
  • Anticoagulants / toxicity*
  • Deoxycholic Acid / analogs & derivatives*
  • Deoxycholic Acid / chemistry
  • Deoxycholic Acid / toxicity
  • Drug Administration Schedule
  • Heparin, Low-Molecular-Weight / analogs & derivatives*
  • Heparin, Low-Molecular-Weight / chemistry
  • Heparin, Low-Molecular-Weight / toxicity
  • Macaca fascicularis
  • Male
  • Molecular Structure
  • Toxicity Tests*

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • LMWH-DOCA conjugate
  • Deoxycholic Acid